Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | October 02, 2020 | October 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIMEDX GROUP, INC.
Report date October 02, 2020 · Filed October 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,357 |
Reported balance
After 2020-10-02 transaction · row 1
1 source rowRow 1 · 2020-10-02 · Grant · Acquired 26,236 · Balance 126,357 F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. Award vests after 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. Award vests after 12 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2020 Filed Oct 5, 2020 20:15 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 26,236 | $6.67 | $174,994.12 |
DisclosureSEC source: 0001376339-20-000129 · wf-form4_160192894139327.xml · nonDerivative · entry 1 YESTON NEIL · CIK 0001558397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,357 F1 · shares: Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. Award vests after 12 months. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:30 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 29,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-20-000084 · wf-form4_159674581139829.xml · nonDerivative · entry 1 YESTON NEIL · CIK 0001558397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,121 F1 · security: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. F1 · price: On August 5, 2020, based on the closing stock price on that date ($5.90), the Company fixed the number of shares of common stock subject to a previously-granted restricted stock unit award. Award vests upon the earlier of one year or the 2019 annual meeting of shareholders, and will be settled in common stock upon vesting. The grant is exempt under Rule 16b-3. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:13 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 12,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-17-000095 · wf-form4_149522480106287.xml · nonDerivative · entry 1 YESTON NEIL · CIK 0001558397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,460 F1 · shares: Grant of restricted stock which vests in full on the first anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.